Skip to main content

Table 1 Clinical and demographic characteristics of patients with multidrug resistant Acinetobacter baumannii pneumonia treated with colistin or tigecycline

From: Effectiveness of tigecycline-based versus colistin- based therapy for treatment of pneumonia caused by multidrug-resistant Acinetobacter baumanniiin a critical setting: a matched cohort analysis

Characteristics

Total N = 294

Colistin N = 119

Tigecycline N = 175

p- value

Age

63.8 (18.5)

63.7 (19.5)

63.8 (17.9)

.95

Male

198 (67.3)

86 (72.3)

112 (64)

.16

APACHE II score

22.5 (9.1)

22.8 (9.3)

22.3 (8.9)

.68

Length of hospital stay before enrollment

32.0 (36.9)

33.2 (45.9)

31.2 (29.4)

.64

Underlying diseases

    

 Cardiovascular disease

47 (16.0)

17 (14.3)

30 (17.1)

.63

 Diabetes mellitus

84 (28.6)

33 (27.7)

51 (29.1)

.90

Insulin use

63 (21.4)

28 (23.5)

35 (20)

.47

 Chronic kidney disease

59 (20.1)

28 (23.5)

31 (17.7)

.24

 Liver cirrhosis

13 (4.4)

4 (3.4)

9 (5.1)

.57

 Chronic pulmonary disease

30 (10.2)

15 (12.6)

15 (8.6)

.33

 Malignancy

36 (12.2)

34 (28.6)

2 (1.1)

<.001

 Autoimmune

16 (5.4)

5 (4.2)

11 (6.3)

.60

 Operation history

140 (47.6)

51 (42.9)

89 (50.9)

.19

Combination therapy

    

 Aminoglycoside

4 (1.4)

1 (0.8)

3 (1.7)

.65

 Carbapenem

34 (11.6)

15 (12.6)

19 (10.9)

.65

 Sulbactam

10 (3.4)

2 (1.7)

8 (4.6)

.21

Baseline creatinine (mg/dL)

1.75 (1.47)

1.66 (1.43)

1.81 (1.50)

.40

Duration of treatment

13.7 (12.5)

14.6 (13.7)

13.1 (11.6)

.31

Follow-up duration

32.4 (31.5)

33.1 (30.9)

31.9 (32.0)

.75

  1. APACHE II, acute physiology and chronic health evaluation II.